http://www.mydailyapple.com/news_alert/topfeed/daily 2009-11-20T00:12:58Z tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.clinicalcorrelations.org%2F%3Ffeed%3Drss2%3A%3Fp%3D2040 2009-11-20T00:12:58Z http://www.clinicalcorrelations.org/?feed=rss2

<p><p style="text-align: left;"> <strong> <a href="http://www.clinicalcorrelations.org/wp-content/plugins/feed-statistics.php?url=aHR0cDovL3d3dy5jbGluaWNhbGNvcnJlbGF0aW9ucy5vcmcvd3AtY29udGVudC91cGxvYWRzLzIwMDkvMTEvZmFsbC5qcGc="> <img class="alignleft size-medium wp-image-2041" style="float: left; margin-left: 4px; margin-right: 4px;" title="fall" src="http://www.clinicalcorrelations.org/wp-content/uploads/2009/11/fall-300x200.jpg" alt="fall" width="164" height="112" /> </a>Katie Miro MD</strong> </p> <p style="text-align: left;"> <em>Faculty peer reviewed</em> </p> <p style="text-align: left;">Americans took the time&#160;last week to honor the men and women who fought for our country as Veteran&#8217;s Day was marked with parades and celebration throughout the nation. Clinical Correlations would like to send special thanks&#8230;</p></p>

<p><p style="text-align: left;"> <strong> <a href="http://www.clinicalcorrelations.org/wp-content/plugins/feed-statistics.php?url=aHR0cDovL3d3dy5jbGluaWNhbGNvcnJlbGF0aW9ucy5vcmcvd3AtY29udGVudC91cGxvYWRzLzIwMDkvMTEvZmFsbC5qcGc="> <img class="alignleft size-medium wp-image-2041" style="float: left; margin-left: 4px; margin-right: 4px;" title="fall" src="http://www.clinicalcorrelations.org/wp-content/uploads/2009/11/fall-300x200.jpg" alt="fall" width="164" height="112" /> </a>Katie Miro MD</strong> </p> <p style="text-align: left;"> <em>Faculty peer reviewed</em> </p> <p style="text-align: left;">Americans took the time&#160;last week to honor the men and women who fought for our country as Veteran&#8217;s Day was marked with parades and celebration throughout the nation. Clinical Correlations would like to send special thanks&#8230;</p></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medicalnewstoday.com%2Fmedicalnews.xml%3Aarticles%2F171064.php 2009-11-20T00:12:58Z http://www.medicalnewstoday.com/medicalnews.xml

<p>The Royal Australian College of General Practitioners (RACGP) warmly welcomes the two pronged themes of prevention of and education that are the focus of World Diabetes Day (14 November). "Recent research is predicting that one in seven Australians will have type 2 diabetes by 2050," said RACGP president, Dr Chris Mitchell. <p> <a href="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/0/da"> <img src="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/0/di" border="0" ismap="true" /> </a> <br /> <a href="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/1/da"> <img src="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/1/di" border="0" ismap="true" /> </a> </p> <img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/OWhWf49o00w" height="1" width="1" /></p>

<p>The Royal Australian College of General Practitioners (RACGP) warmly welcomes the two pronged themes of prevention of and education that are the focus of World Diabetes Day (14 November). "Recent research is predicting that one in seven Australians will have type 2 diabetes by 2050," said RACGP president, Dr Chris Mitchell. <p> <a href="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/0/da"> <img src="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/0/di" border="0" ismap="true" /> </a> <br /> <a href="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/1/da"> <img src="http://feedads.g.doubleclick.net/~a/xRt8mQj7-aol85EzGvqsAQMXK38/1/di" border="0" ismap="true" /> </a> </p> <img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/OWhWf49o00w" height="1" width="1" /></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medicalnewstoday.com%2Fmedicalnews.xml%3Aarticles%2F170977.php 2009-11-20T00:12:58Z http://www.medicalnewstoday.com/medicalnews.xml

<p>Low birth weight increases the risk of developing type 2 diabetes later in life. Until recently scientists had attributed this to maternal malnutrition during pregnancy. However, now it seems that genetic background may also play a major role. <p> <a href="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/0/da"> <img src="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/0/di" border="0" ismap="true" /> </a> <br /> <a href="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/1/da"> <img src="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/1/di" border="0" ismap="true" /> </a> </p> <img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/1jfc_3YU50k" height="1" width="1" /></p>

<p>Low birth weight increases the risk of developing type 2 diabetes later in life. Until recently scientists had attributed this to maternal malnutrition during pregnancy. However, now it seems that genetic background may also play a major role. <p> <a href="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/0/da"> <img src="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/0/di" border="0" ismap="true" /> </a> <br /> <a href="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/1/da"> <img src="http://feedads.g.doubleclick.net/~a/S0IM2V0dFg3hwFHyxRoVMy2mgrs/1/di" border="0" ismap="true" /> </a> </p> <img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/1jfc_3YU50k" height="1" width="1" /></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.neurology.org%3Ahttp%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F73%2F20%2F1681%3Frss%3D1 2009-11-20T00:12:58Z http://www.neurology.org

<p><p> <b>Background:</b> Recently hyperlipidemia was reported to be related to a significantly better outcome in amyotrophic lateral sclerosis (ALS). To investigate this, we evaluated the status of blood lipids in a large Italian series of patients with ALS, and assessed the effect of hyperlipidemia on patients&#8217; survival.</p> <p> <b>Methods:</b> The study population included 658 patients with ALS consecutively observed in 2 Italian ALS centers between 2000 and 2006. They were compared to a series of 658 healthy subjects, matched by age and gender.</p> <p> <b>Results:</b> The mean levels of total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the LDL/HDL ratio were similar in patients with ALS and controls. Total cholesterol, HDL, triglyceride, and LDL/HDL ratio levels showed a significant decrease in patients with forced vital capacity &lt;70% compared to those with FVC &#8805;90%. For each level of ALS-FRS, poorer respiratory function was related to a lower LDL/HDL ratio. Univariate survival analysis did not find any significant effect of LDL/HDL ratio on survival, either when comparing patients with ratios &#8804;2.99 vs &gt;2.99 or patients in the first quartile of LDL/HDL ratio (&#8804;1.67) vs those in the fourth quartile (&gt;2.79). No dose-response was found for LDL/HDL ratio subdividing patients into 5 quintiles.</p> <p> <b>Conclusion:</b> Our findings do not support the observation that patients with amyotrophic lateral sclerosis have hyperlipidemia or that hyperlipidemia in this population is related to longer survival. However, some evidence emerged that respiratory impairment, but not a worse clinical status or a lower body mass index, is related to a decrease in blood lipids and LDL/HDL ratio.</p></p>

<p><p> <b>Background:</b> Recently hyperlipidemia was reported to be related to a significantly better outcome in amyotrophic lateral sclerosis (ALS). To investigate this, we evaluated the status of blood lipids in a large Italian series of patients with ALS, and assessed the effect of hyperlipidemia on patients&#8217; survival.</p> <p> <b>Methods:</b> The study population included 658 patients with ALS consecutively observed in 2 Italian ALS centers between 2000 and 2006. They were compared to a series of 658 healthy subjects, matched by age and gender.</p> <p> <b>Results:</b> The mean levels of total cholesterol, triglycerides, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and the LDL/HDL ratio were similar in patients with ALS and controls. Total cholesterol, HDL, triglyceride, and LDL/HDL ratio levels showed a significant decrease in patients with forced vital capacity &lt;70% compared to those with FVC &#8805;90%. For each level of ALS-FRS, poorer respiratory function was related to a lower LDL/HDL ratio. Univariate survival analysis did not find any significant effect of LDL/HDL ratio on survival, either when comparing patients with ratios &#8804;2.99 vs &gt;2.99 or patients in the first quartile of LDL/HDL ratio (&#8804;1.67) vs those in the fourth quartile (&gt;2.79). No dose-response was found for LDL/HDL ratio subdividing patients into 5 quintiles.</p> <p> <b>Conclusion:</b> Our findings do not support the observation that patients with amyotrophic lateral sclerosis have hyperlipidemia or that hyperlipidemia in this population is related to longer survival. However, some evidence emerged that respiratory impairment, but not a worse clinical status or a lower body mass index, is related to a decrease in blood lipids and LDL/HDL ratio.</p></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Ffeeds.feedburner.com%2FXconomy_Full%3Ahttp%3A%2F%2Fwww.xconomy.com%2F%3Fp%3D50780 2009-11-19T00:07:28Z http://feeds.feedburner.com/Xconomy_Full

<p>Google, Yahoo, Facebook, MySpace. Those companies&#8217; products spread over the Internet like a virus. But why hasn&#8217;t there been a runaway hit like those in the mobile software world? Why does it take so much longer to build value, and a strong customer base, in mobile companies than in certain Internet startups? Dan Shapiro had some [...] <br clear="both" style="clear: both;" /> <br clear="both" style="clear: both;" /> <a href="http://ads.pheedo.com/click.phdo?s=b010770a8af8dfad0ca0bdc6ce092e9d&amp;p=1"> <img alt="" style="border: 0;" border="0" src="http://ads.pheedo.com/img.phdo?s=b010770a8af8dfad0ca0bdc6ce092e9d&amp;p=1" /> </a> <img alt="" height="0" width="0" border="0" style="display:none" src="http://a.rfihub.com/eus.gif?eui=2218" /></p>

<p>Google, Yahoo, Facebook, MySpace. Those companies&#8217; products spread over the Internet like a virus. But why hasn&#8217;t there been a runaway hit like those in the mobile software world? Why does it take so much longer to build value, and a strong customer base, in mobile companies than in certain Internet startups? Dan Shapiro had some [...] <br clear="both" style="clear: both;" /> <br clear="both" style="clear: both;" /> <a href="http://ads.pheedo.com/click.phdo?s=b010770a8af8dfad0ca0bdc6ce092e9d&amp;p=1"> <img alt="" style="border: 0;" border="0" src="http://ads.pheedo.com/img.phdo?s=b010770a8af8dfad0ca0bdc6ce092e9d&amp;p=1" /> </a> <img alt="" height="0" width="0" border="0" style="display:none" src="http://a.rfihub.com/eus.gif?eui=2218" /></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.neurology.org%3Ahttp%3A%2F%2Fwww.neurology.org%2Fcgi%2Fcontent%2Fshort%2F73%2F20%2F1677%3Frss%3D1 2009-11-19T00:07:28Z http://www.neurology.org

<p><p> <b>Background:</b> Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed.</p> <p> <b>Methods:</b> In this Institutional Review Board&#8211;approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression (TTP), and median overall survival (OS; Kaplan-Meier method).</p> <p> <b>Results:</b> There were 4 men and 4 women with a median age of 40 years (range, 20&#8211;65). Prior treatment included surgery (n = 8), RT (8), temozolomide (5), and carboplatin (4). Bevacizumab (5&#8211;15 mg/kg every 2&#8211;3 weeks) was administered alone (2) or concurrently with cytotoxic chemotherapy including irinotecan (3), carboplatin (2), or temozolomide (1). Six patients achieved a partial response (75%) and 1 remained stable for over 8 months. Median TTP was 6.4 months (95% confidence interval 1.4&#8211;7.4) and median OS was 9.4 months (95% confidence interval 7.0&#8211;not reached), with a median follow-up of 5.2 months among 5 surviving patients (63%).</p> <p> <b>Conclusions:</b> The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.</p></p>

<p><p> <b>Background:</b> Ependymoma is a rare type of glioma, representing 5% of all CNS malignancies. Radiotherapy (RT) is commonly administered, but there is no standard chemotherapy. At recurrence, ependymoma is notoriously refractory to therapy and the prognosis is poor. In recurrent glioblastoma, encouraging responses with bevacizumab have been observed.</p> <p> <b>Methods:</b> In this Institutional Review Board&#8211;approved study, we retrospectively analyzed the records of 8 adult patients treated for recurrent ependymoma and anaplastic ependymoma with bevacizumab containing chemotherapy regimens. We determined radiographic response (Macdonald criteria), median time to progression (TTP), and median overall survival (OS; Kaplan-Meier method).</p> <p> <b>Results:</b> There were 4 men and 4 women with a median age of 40 years (range, 20&#8211;65). Prior treatment included surgery (n = 8), RT (8), temozolomide (5), and carboplatin (4). Bevacizumab (5&#8211;15 mg/kg every 2&#8211;3 weeks) was administered alone (2) or concurrently with cytotoxic chemotherapy including irinotecan (3), carboplatin (2), or temozolomide (1). Six patients achieved a partial response (75%) and 1 remained stable for over 8 months. Median TTP was 6.4 months (95% confidence interval 1.4&#8211;7.4) and median OS was 9.4 months (95% confidence interval 7.0&#8211;not reached), with a median follow-up of 5.2 months among 5 surviving patients (63%).</p> <p> <b>Conclusions:</b> The radiographic response rate to bevacizumab-containing regimens is high. A prospective study is warranted.</p></p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medicalnewstoday.com%2Frss%2Fcancer-oncology.xml%3A%2Farticles%2F171172.php 2009-11-19T00:07:28Z http://www.medicalnewstoday.com/rss/cancer-oncology.xml

<p>Paul Allen who co-founded the computer giant Microsoft with Bill Gates in the 1970s has been diagnosed with Non-Hodgkin's Lymphoma, 25 years after surviving Hodgkin's lymphoma. The news was announced in a memo to the staff of Allen's company Vulcan, by CEO Jody Allen, who is also Paul Allen's sister. A copy of the memo was also sent to the media.</p>

<p>Paul Allen who co-founded the computer giant Microsoft with Bill Gates in the 1970s has been diagnosed with Non-Hodgkin's Lymphoma, 25 years after surviving Hodgkin's lymphoma. The news was announced in a memo to the staff of Allen's company Vulcan, by CEO Jody Allen, who is also Paul Allen's sister. A copy of the memo was also sent to the media.</p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medworm.com%2Frss%2Fmedicalfeeds%2Fspecialities%2FConsumer-Health-News.xml%3A2989452 2009-11-19T00:07:28Z http://www.medworm.com/rss/medicalfeeds/specialities/Consumer-Health-News.xml

<p>"Survivor" winner Ethan Zohn is documenting his battle with Hodgkins Disease in the hopes of educating others. (Source: Health News: CBSNews.com)</p>

<p>"Survivor" winner Ethan Zohn is documenting his battle with Hodgkins Disease in the hopes of educating others. (Source: Health News: CBSNews.com)</p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medicinenet.com%2Frss%2Fdailyhealth.xml%3A%2Fguide.asp%3Fs%3Drss%26k%3DDailyHealth%26a%3D107496 2009-11-18T00:13:32Z http://www.medicinenet.com/rss/dailyhealth.xml

<p>Title: Kareem Abdul-Jabbar Has CML Form of Leukemia <br />Category: Health News <br />Created: 11/11/2009 9:41:00 AM <br />Last Editorial Review: 11/11/2009 9:41:07 AM</p>

<p>Title: Kareem Abdul-Jabbar Has CML Form of Leukemia <br />Category: Health News <br />Created: 11/11/2009 9:41:00 AM <br />Last Editorial Review: 11/11/2009 9:41:07 AM</p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medworm.com%2Frss%2Fmedicalfeeds%2Fspecialities%2FConsumer-Health-News.xml%3A2977820 2009-11-18T00:13:32Z http://www.medworm.com/rss/medicalfeeds/specialities/Consumer-Health-News.xml

<p>The US Food and Drug Administration has granted orphan drug designation for voreloxin in the treatment of acute myeloid leukemia. Medscape Medical News (Source: Medscape Today Headlines)</p>

<p>The US Food and Drug Administration has granted orphan drug designation for voreloxin in the treatment of acute myeloid leukemia. Medscape Medical News (Source: Medscape Today Headlines)</p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.sciencedaily.com%2Frss%2Fhealth_medicine.xml%3A%2Freleases%2F2009%2F11%2F091110090905.htm 2009-11-18T00:13:32Z http://www.sciencedaily.com/rss/health_medicine.xml

<p>The drug Sprycel, approved for use by the US Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a new study has found.</p>

<p>The drug Sprycel, approved for use by the US Food and Drug Administration in patients with chronic myeloid leukemia, significantly inhibited the growth and invasiveness of ovarian cancer cells and also promoted their death, a new study has found.</p> tag:praxeon.com,2007:s3%3Ahttp%253A%2F%2Fwww.medworm.com%2Frss%2Fmedicalfeeds%2Fspecialities%2FConsumer-Health-News.xml%3A2989913 2009-11-18T00:13:32Z http://www.medworm.com/rss/medicalfeeds/specialities/Consumer-Health-News.xml

<p>Kitty Walker (Calista Flockhart) is thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. Kitty Walker (Calista Flockhart) s thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. (Source: L.A. Times - Health)</p>

<p>Kitty Walker (Calista Flockhart) is thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. Kitty Walker (Calista Flockhart) s thinking of turning to flaxseed oil and herbs to cure her non-Hodgkin's lymphoma. (Source: L.A. Times - Health)</p>